HSBC Cuts Zoetis Inc. (ZTS)'s Price Target To $140 From $180, Keeps Buy Rating

Zoetis Inc. (NYSE:ZTS) is among the 11 Most Oversold S&P 500 Stocks Heading into 2026. On December 10, HSBC slashed its price target on the stock to $140 from $180, as part of the firm’s broader overview of pharmaceutical stocks for 2026.

However, the investment bank maintained its earlier Buy rating for the shares. It stated that it expects the sector to outperform next year, “even more so if AI panic kicks in,” according to a report by TipRanks.

In other related news, Barclays initiated coverage of Zoetis Inc. (NYSE:ZTS) on December 8 with an Equal-Weight rating and set a share price target of $136. The firm said it has a neutral outlook for the specialty pharmaceuticals sector as a shift toward innovation and margin expansion drives investor confidence.

In a research note to investors, Barclays further noted that deleveraging was helping to counter pricing challenges faced by pharmaceutical companies, which could potentially lead to significant opportunities for the industry.

As of the close of business on December 10, Wall Street analysts have a Moderate Buy rating for the stock, with a one-year average share price target of $161.03, representing an upside potential of 38%.

Zoetis Inc. (NYSE:ZTS) produces vaccines and medications for animal health. The stock has had a difficult 2025 and is down 28% year-to-date.

While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 15 Lowest P/E Ratios of the S&P 500 in 2025 and 10 Best Drone Stocks to Buy Right Now.

Disclosure: None.